InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain
InhaleRX Ltd has received approval for a Phase 2 clinical trial to test its novel therapy IRX-211 for treatment of Breakthrough Cancer Pain
IAD
0.00%
60.0¢
Inverloch & District Financial Enterprises Limited
Currently unlisted.
Add to my watchlist
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
IAD | Ann:Half Yearly Financial Statements - 31 December 201 (Price Sensitive) | 12/03/19 | 0 | 256 | |||
|
|||||||
IAD | Ann:Appointment of Office Bearers | 27/12/18 | 0 | 356 | |||
|
|||||||
IAD | Ann:Results of 2018 AGM | 27/11/18 | 0 | 335 | |||
|
|||||||
IAD | Ann:Notice of 2018 AGM | 22/10/18 | 0 | 220 | |||
|
|||||||
IAD | Ann:Proxy Form | 22/10/18 | 0 | 234 | |||
|
|||||||
IAD | Ann:Annual Report - 30 June 2018 (Price Sensitive) | 22/10/18 | 0 | 389 | |||
|
|||||||
IAD | Ann:Dividend Notification | 20/09/18 | 0 | 707 | |||
|
|||||||
IAD | Ann:Preliminary Final Report and Financial Statements - 30 June 2018 (Price Sensitive) | 04/09/18 | 0 | 646 | |||
|
See All Discussions